Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroSense TherapeuticsNRSN +0.95%31 EV-to-OCF is -2.35 as of Aug. 10, 2026. GuruFocus rates NRSN with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,407 Biotechnology companies, NeuroSense Therapeutics ranks worse than 56.57% on this metric.
The historical rank and industry rank for NeuroSense Therapeutics's EV-to-OCF or its related term are showing as below:
NRSN'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.35 Med: 0 Max: -2.35
Current: -2.35
During the past 7 years, the highest EV-to-OCF of NeuroSense Therapeutics was -2.35. The lowest was -2.35. And the median was .
NRSN's EV-to-OCF is ranked worse than 56.57% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs NRSN: -2.35
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NeuroSense Therapeutics's PE Ratio (TTM) for today is calculated as:
NeuroSense Therapeutics's share price for today is $0.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NeuroSense Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NeuroSense Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroSense Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where NeuroSense Therapeutics's EV-to-OCF falls into.
NeuroSense Therapeutics's current Enterprise Value is $18.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NeuroSense Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-7.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroSense Therapeutics (NRSN) has a EV-to-OCF of -2.35 as of Aug. 10, 2026. According to the industry distribution chart, NeuroSense Therapeutics ranks #796 out of 1407 companies in the Biotechnology industry, placing it in the top 56.6%.
Is NeuroSense Therapeutics' EV-to-OCF too high?
NeuroSense Therapeutics' current EV-to-OCF is -2.35. Based on the distribution chart, NeuroSense Therapeutics ranks #796 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NeuroSense Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' EV-to-OCF compare to CELU and GRDX?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #796 out of 1407 companies for EV-to-OCF. This places NeuroSense Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. NeuroSense Therapeutics's current EV-to-OCF is -2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current EV-to-OCF of -2.35. The current EV-to-OCF is -2.35. NeuroSense Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current EV-to-OCF is -2.35 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
31GF Score
Get the complete analysis for NRSN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRSN has been successfully added to your 
